VALIDATE Winter Seminar: A flexible and efficient platform to develop a nanovaccine against Burkholderia pseudomallei

The Seminar took Place 16 November 2022

About the Seminar

Antigen-delivery vaccine platforms that promote humoral and cellular responses while maintaining a safe profile are a roadblock to developing subunit vaccines against Burkholderia pseudomallei. The Torres Lab at UTMB has used gold nanoparticles for the delivery of multicomponent antigens, identified by the bio-immunoinformatic analysis, that is able to induce vaccine-mediated immunity, promoting protection against melioidosis disease. In this talk, Prof Alfredo G Torres will discussed his team's latest research on nanovaccines.

About the Speaker

Professor Alfredo G. Torres, PhD, MS is the Herman Barnett Distinguished Professor in Microbiology and Immunology and associate Provost for Faculty Affairs and Diversity, Equity and Inclusion for the Academic Enterprise at the University of Texas Medical Branch.

His lab is pursuing studies to understand the pathogenic process of Shiga toxin-producing E. coli (STEC) and other pathogenic E. coli strains, and the interaction of these pathogens with the intestinal mucosa, with most of these studies combining genetic approaches and animal model testing.His research group has contributed to the knowledge of pathogenic E. coli virulence factors, particularly those adhesins associated with human infections, to define the bacterial factors mediatinal tissue tropism, and to their understanding of immunogenic antigens and their value as vaccine candidates. In the case of Burkholderia pathogenesis, they have advanced the field of host immune responses to infection, and have identified novel immunogenic antigens as effective vaccine candidates.


Alfredo G Torres